Introducing a simplified approach to insulin therapy in type 2 diabetes: A comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs

Diabetes, Obesity and Metabolism

Volumn 10, Issue 12, 2008, Pages 1178-1185

  Lankisch, Mark ^a,e   Ferlinz, K C ^b   Leahy, J L ^c   Scherbaum, W A ^a,d  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^e Herzzentrum Wuppertal Medizinische Klinik III Abteilung Kardiologie   (Germany)

Author keywords

Antidiabetic drugs; Diabetes mellitus; HbA1c; Insulin analogue

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; INSULIN GLULISINE; ORAL ANTIDIABETIC AGENT; SULFONAMIDE; THIAZOLIDINE DERIVATIVE; UREA DERIVATIVE;

ADD ON THERAPY; ADULT; ARTICLE; BODY MASS; BODY WEIGHT; BOLUS INJECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MEAL; MORNING DOSAGE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

EID: 55449131463     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.00967.x     Document Type: Article

References (23)

1. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-853.
2. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854-865.
3. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117.
4. American Diabetes Association. Standards of medical care in diabetes - 2007. Diabetes Care 2007; 30: S4-S41.
5. International Diabetes Federation. Global Guidelines for Type 2 Diabetes. Brussels: 2005.
6. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29: 1963-1972.
7. DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: Scientific review. JAMA 2003; 289: 2254-2264.
8. Hirsch IB. Insulin analogues. N Engl J Med 2005; 352: 174-183.
9. Wright A. Sulfonylurea inadequacy: Efficacy of addition of insulin over 6years in patients with type 2 diabetes in the UK. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002; 25: 330-336.
10. Nelson SE, Palumbo PJ. Addition of insulin to oral therapy in patients with type 2 diabetes. Am J Med Sci 2006; 331: 257-263.
11. Kuritzky L. Addition of basal insulin to oral antidiabetic agents: A goal-directed approach to type 2 diabetes therapy. MedGenMed 2006; 8: 34.
12. Hirsch IB, Bergenstal RM, Parkin CG, Wright E Jr, Buse JB. A real-world approach to insulin therapy in primary care practice. Clin Diabetes 2005; 23: 78-86.
13. Leahy JL. Basal-prandial insulin therapy: Scientific concept review and application. Am J Med Sci 2006; 332: 24-31.
14. Monnier L, Colette C. Addition of rapid-acting insulin to basal insulin therapy in type 2 diabetes: Indications and modalities. Diabetes Metab 2006; 32: 7-13.
15. Cryer P, Childs BP. Negotiating the barrier of hypoglycemia in diabetes. Diabetes Spectr 2002; 15: 20-27.
16. Korytkowski M. When oral agents fail: Practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002; 26: S18-S24.
17. Meece J. Dispelling myths and removing barriers about insulin in type 2 diabetes. Diabetes Educ 2006; 32: 9S-18S.
18. Raccah D, Bretzel RG, Owens D, Riddle M. When basal insulin therapy in type 2 diabetes mellitus is not enough-what next? Diabetes Metab Res Rev 2007; 23: 257-264.
19. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: Variations with increasing levels of HbA(1c). Diabetes Care 2003; 26: 881-885.
20. Monnier L, Colette C, Dunseath GJ, Owens DR. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 2007; 30: 263-269.
21. Bethel MA, Feinglos MN. Basal insulin therapy in type 2 diabetes. J Am Board Fam Pract 2005; 18: 199-204.
22. American Diabetes Association. Standards of medical care in diabetes-2006. Diabetes Care 2006; 29 (Suppl. 1): S4-S42.
23. Gale EA, Beattie SD, Hu J, Koivisto V, Tan MH. Recruitment to a clinical trial improves glycemic control in patients with diabetes. Diabetes Care 2007; 30: 2989-2992.